Publication: Targeting gut microbiome, is it always a therapeutic option?
dc.contributor.author | Rodríguez-Nogales, Alba | |
dc.contributor.author | Gálvez, Julio | |
dc.date.accessioned | 2023-02-09T09:47:10Z | |
dc.date.available | 2023-02-09T09:47:10Z | |
dc.date.issued | 2020-11-09 | |
dc.description.abstract | Obstructive sleep apnea (OSA) is a common respiratory disorder associated with cardiovascular comorbidities and cancer due to chronic intermittent hypoxia (CIH). This condition affects the gut microbiome, altering its diversity and increasing intestinal permeability, which contributes to insulin resistance. Dysbiosis is linked to chronic diseases such as metabolic syndrome and cardiovascular disorders. | |
dc.description.version | Si | |
dc.identifier.citation | Rodríguez-Nogales A, Gálvez J. Targeting gut microbiome, is it always a therapeutic option? EBioMedicine. 2020 Dec;62:103099. doi: 10.1016/j.ebiom.2020.103099. | |
dc.identifier.doi | 10.1016/j.ebiom.2020.103099 | |
dc.identifier.essn | 2352-3964 | |
dc.identifier.issn | 2352-3964 | |
dc.identifier.pmc | PMC7656137 | |
dc.identifier.pmid | 33161230 | |
dc.identifier.pubmedURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656137/pdf | |
dc.identifier.unpaywallURL | https://doi.org/10.1016/j.ebiom.2020.103099 | |
dc.identifier.uri | http://hdl.handle.net/10668/16566 | |
dc.journal.title | EBioMedicine | |
dc.journal.titleabbreviation | EBioMedicine | |
dc.language.iso | en | |
dc.organization | Hospital Universitario Virgen de las Nieves | |
dc.organization | Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA) | |
dc.page.number | 103099 | |
dc.provenance | Curación de contenido realizada 09/09/2024 | |
dc.publisher | The Lancet Publishing Group | |
dc.pubmedtype | Letter | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | Obstructive sleep apnea (OSA) | |
dc.subject | Chronic intermittent hypoxia (CIH) | |
dc.subject | Gut microbiome | |
dc.subject | Oxidative stress | |
dc.subject | Insulin resistance | |
dc.subject.decs | Apnea obstructiva del sueño (AOS) | |
dc.subject.decs | Hipoxia intermitente crónica (HIC) | |
dc.subject.decs | Disbiosis del microbioma intestinal | |
dc.subject.decs | Sistema nervioso simpático | |
dc.subject.decs | Enfermedades cardiovasculares y comorbilidades | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Disease Management | |
dc.subject.mesh | Disease Susceptibility | |
dc.subject.mesh | Gastrointestinal Microbiome | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Precision Medicine | |
dc.title | Targeting gut microbiome, is it always a therapeutic option? | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 62 | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1